Ethics and the pharmaceutical industry:
Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Cambridge University Press
2005
|
| Schlagworte: | |
| Online-Zugang: | BSB01 UBG01 URL des Erstveröffentlichers |
| Zusammenfassung: | Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing |
| Beschreibung: | Title from publisher's bibliographic system (viewed on 05 Oct 2015) |
| Beschreibung: | 1 online resource (xxxiv, 492 pages) |
| ISBN: | 9780511610769 |
| DOI: | 10.1017/CBO9780511610769 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043925741 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161202s2005 |||| o||u| ||||||eng d | ||
| 020 | |a 9780511610769 |c Online |9 978-0-511-61076-9 | ||
| 024 | 7 | |a 10.1017/CBO9780511610769 |2 doi | |
| 035 | |a (ZDB-20-CBO)CR9780511610769 | ||
| 035 | |a (OCoLC)732170609 | ||
| 035 | |a (DE-599)BVBBV043925741 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-473 | ||
| 082 | 0 | |a 338.4/76151 |2 22 | |
| 084 | |a PI 4580 |0 (DE-625)136631: |2 rvk | ||
| 245 | 1 | 0 | |a Ethics and the pharmaceutical industry |c edited by Michael A. Santoro, Thomas M. Gorrie |
| 246 | 1 | 3 | |a Ethics & the Pharmaceutical Industry |
| 264 | 1 | |a Cambridge |b Cambridge University Press |c 2005 | |
| 300 | |a 1 online resource (xxxiv, 492 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from publisher's bibliographic system (viewed on 05 Oct 2015) | ||
| 505 | 8 | |a Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams | |
| 505 | 8 | |a A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski | |
| 505 | 8 | |a Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman | |
| 520 | |a Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing | ||
| 650 | 4 | |a Ethik | |
| 650 | 4 | |a Gesellschaft | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Drugs / Marketing / Moral and ethical aspects | |
| 650 | 4 | |a Drugs / Research / Moral and ethical aspects | |
| 650 | 4 | |a Medical innovations / Social aspects | |
| 650 | 4 | |a Social responsibility of business | |
| 650 | 0 | 7 | |a Soziale Verantwortung |0 (DE-588)4055737-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Ethik |0 (DE-588)4015602-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 1 | |a Soziale Verantwortung |0 (DE-588)4055737-6 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 1 | 1 | |a Ethik |0 (DE-588)4015602-3 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Santoro, Michael A. |4 edt | |
| 700 | 1 | |a Gorrie, Thomas M. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-70888-3 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-85496-2 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/CBO9780511610769 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-20-CBO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029334820 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511610769 |l BSB01 |p ZDB-20-CBO |q BSB_PDA_CBO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511610769 |l UBG01 |p ZDB-20-CBO |q UBG_PDA_CBO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176852312391680 |
|---|---|
| any_adam_object | |
| author2 | Santoro, Michael A. Gorrie, Thomas M. |
| author2_role | edt edt |
| author2_variant | m a s ma mas t m g tm tmg |
| author_facet | Santoro, Michael A. Gorrie, Thomas M. |
| building | Verbundindex |
| bvnumber | BV043925741 |
| classification_rvk | PI 4580 |
| collection | ZDB-20-CBO |
| contents | Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman |
| ctrlnum | (ZDB-20-CBO)CR9780511610769 (OCoLC)732170609 (DE-599)BVBBV043925741 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Rechtswissenschaft Wirtschaftswissenschaften |
| doi_str_mv | 10.1017/CBO9780511610769 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06137nmm a2200709zc 4500</leader><controlfield tag="001">BV043925741</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161202s2005 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780511610769</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-511-61076-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1017/CBO9780511610769</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-20-CBO)CR9780511610769</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)732170609</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043925741</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-473</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PI 4580</subfield><subfield code="0">(DE-625)136631:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ethics and the pharmaceutical industry</subfield><subfield code="c">edited by Michael A. Santoro, Thomas M. Gorrie</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Ethics & the Pharmaceutical Industry</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxxiv, 492 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from publisher's bibliographic system (viewed on 05 Oct 2015)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ethik</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gesellschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Marketing / Moral and ethical aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Research / Moral and ethical aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical innovations / Social aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social responsibility of business</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Soziale Verantwortung</subfield><subfield code="0">(DE-588)4055737-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ethik</subfield><subfield code="0">(DE-588)4015602-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Soziale Verantwortung</subfield><subfield code="0">(DE-588)4055737-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Ethik</subfield><subfield code="0">(DE-588)4015602-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoro, Michael A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gorrie, Thomas M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-70888-3</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-85496-2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1017/CBO9780511610769</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-20-CBO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029334820</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511610769</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">BSB_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511610769</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">UBG_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV043925741 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:38:46Z |
| institution | BVB |
| isbn | 9780511610769 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029334820 |
| oclc_num | 732170609 |
| open_access_boolean | |
| owner | DE-12 DE-473 DE-BY-UBG |
| owner_facet | DE-12 DE-473 DE-BY-UBG |
| physical | 1 online resource (xxxiv, 492 pages) |
| psigel | ZDB-20-CBO ZDB-20-CBO BSB_PDA_CBO ZDB-20-CBO UBG_PDA_CBO |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | Cambridge University Press |
| record_format | marc |
| spelling | Ethics and the pharmaceutical industry edited by Michael A. Santoro, Thomas M. Gorrie Ethics & the Pharmaceutical Industry Cambridge Cambridge University Press 2005 1 online resource (xxxiv, 492 pages) txt rdacontent c rdamedia cr rdacarrier Title from publisher's bibliographic system (viewed on 05 Oct 2015) Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing Ethik Gesellschaft Pharmaceutical industry Drugs / Marketing / Moral and ethical aspects Drugs / Research / Moral and ethical aspects Medical innovations / Social aspects Social responsibility of business Soziale Verantwortung (DE-588)4055737-6 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Ethik (DE-588)4015602-3 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Pharmazeutische Industrie (DE-588)4045696-1 s Soziale Verantwortung (DE-588)4055737-6 s 2\p DE-604 Arzneimittelentwicklung (DE-588)4143176-5 s Ethik (DE-588)4015602-3 s 3\p DE-604 Santoro, Michael A. edt Gorrie, Thomas M. edt Erscheint auch als Druckausgabe 978-0-521-70888-3 Erscheint auch als Druckausgabe 978-0-521-85496-2 https://doi.org/10.1017/CBO9780511610769 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Ethics and the pharmaceutical industry Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman Ethik Gesellschaft Pharmaceutical industry Drugs / Marketing / Moral and ethical aspects Drugs / Research / Moral and ethical aspects Medical innovations / Social aspects Social responsibility of business Soziale Verantwortung (DE-588)4055737-6 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Ethik (DE-588)4015602-3 gnd |
| subject_GND | (DE-588)4055737-6 (DE-588)4045696-1 (DE-588)4143176-5 (DE-588)4015602-3 (DE-588)4143413-4 |
| title | Ethics and the pharmaceutical industry |
| title_alt | Ethics & the Pharmaceutical Industry |
| title_auth | Ethics and the pharmaceutical industry |
| title_exact_search | Ethics and the pharmaceutical industry |
| title_full | Ethics and the pharmaceutical industry edited by Michael A. Santoro, Thomas M. Gorrie |
| title_fullStr | Ethics and the pharmaceutical industry edited by Michael A. Santoro, Thomas M. Gorrie |
| title_full_unstemmed | Ethics and the pharmaceutical industry edited by Michael A. Santoro, Thomas M. Gorrie |
| title_short | Ethics and the pharmaceutical industry |
| title_sort | ethics and the pharmaceutical industry |
| topic | Ethik Gesellschaft Pharmaceutical industry Drugs / Marketing / Moral and ethical aspects Drugs / Research / Moral and ethical aspects Medical innovations / Social aspects Social responsibility of business Soziale Verantwortung (DE-588)4055737-6 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Ethik (DE-588)4015602-3 gnd |
| topic_facet | Ethik Gesellschaft Pharmaceutical industry Drugs / Marketing / Moral and ethical aspects Drugs / Research / Moral and ethical aspects Medical innovations / Social aspects Social responsibility of business Soziale Verantwortung Pharmazeutische Industrie Arzneimittelentwicklung Aufsatzsammlung |
| url | https://doi.org/10.1017/CBO9780511610769 |
| work_keys_str_mv | AT santoromichaela ethicsandthepharmaceuticalindustry AT gorriethomasm ethicsandthepharmaceuticalindustry AT santoromichaela ethicsthepharmaceuticalindustry AT gorriethomasm ethicsthepharmaceuticalindustry |